Back to Search
Start Over
Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy
- Source :
- Blood; January 1984, Vol. 63 Issue: 1 p211-212, 2p
- Publication Year :
- 1984
-
Abstract
- Remission rates for patients with acute promyelocytic leukemia (APL) have improved with the use of anthracyclines and proper management of disseminated intravascular coagulopathy. In a prospective randomized trial of chemotherapy in patients with acute nonlymphoblastic leukemia, there were 16 patients with APL. All 7 of the patients receiving the amsacrine-containing regimen and 5 of 9 receiving the daunorubicin- containing regimen achieved a remission. All patients, except 2 of the 3 who underwent bone marrow transplantation, remain alive and in remission from 1+ to 25+ mo. Amsacrine is an effective replacement for daunorubicin in the treatment of APL, and its use does not compromise the favorable remission duration characteristic of APL.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 63
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs52894576
- Full Text :
- https://doi.org/10.1182/blood.V63.1.211.211